- Home
- KLRS vs OCCI Comparison
KLRS vs OCCI Comparison
Compare KLRS & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLRS
- OCCI
- Stock Information
- Founded
- KLRS 2019
- OCCI N/A
- Country
- KLRS United States
- OCCI United States
- Employees
- KLRS N/A
- OCCI N/A
- Industry
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- KLRS Health Care
- OCCI Finance
- Exchange
- KLRS Nasdaq
- OCCI Nasdaq
- Market Cap
- KLRS 129.0M
- OCCI 146.8M
- IPO Year
- KLRS N/A
- OCCI N/A
- Fundamental
- Price
- KLRS $3.89
- OCCI $6.72
- Analyst Decision
- KLRS Buy
- OCCI
- Analyst Count
- KLRS 1
- OCCI 0
- Target Price
- KLRS N/A
- OCCI N/A
- AVG Volume (30 Days)
- KLRS 62.9K
- OCCI 115.8K
- Earning Date
- KLRS 05-19-2025
- OCCI 12-11-2023
- Dividend Yield
- KLRS N/A
- OCCI 24.32%
- EPS Growth
- KLRS N/A
- OCCI N/A
- EPS
- KLRS N/A
- OCCI N/A
- Revenue
- KLRS N/A
- OCCI N/A
- Revenue This Year
- KLRS N/A
- OCCI N/A
- Revenue Next Year
- KLRS N/A
- OCCI $10.19
- P/E Ratio
- KLRS N/A
- OCCI N/A
- Revenue Growth
- KLRS N/A
- OCCI N/A
- 52 Week Low
- KLRS $4.19
- OCCI $5.47
- 52 Week High
- KLRS $24.15
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- KLRS N/A
- OCCI 53.35
- Support Level
- KLRS N/A
- OCCI $6.49
- Resistance Level
- KLRS N/A
- OCCI $6.79
- Average True Range (ATR)
- KLRS 0.00
- OCCI 0.11
- MACD
- KLRS 0.00
- OCCI 0.02
- Stochastic Oscillator
- KLRS 0.00
- OCCI 73.47
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.